Table 4 Gene sets significantly up-regulated or down-regulated 28 days after the end of the medication period (day 35).
Rank | Gene Sets – Up-regulated | Size | Nom P-value | FDR (%) |
|---|---|---|---|---|
Up-regulated | ||||
1 | Protein dimerization activity | 60 | 0.0 | 3.72 |
2 | Second-messenger-mediated signaling | 20 | 0.0 | 1.86 |
3 | Endonuclease activity | 21 | 0.0 | 3.31 |
4 | Protein heterodimerization activity | 29 | 0.0 | 4.75 |
5 | mRNA catabolic process | 20 | 0.0 | 4.74 |
6 | mRNA catabolic process, nonsense-mediated decay | 17 | 0.0 | 6.18 |
7 | Endonuclease activity, active with either ribo- or deoxyribonucleic | |||
acids and producing 5'-phosphomonoesters | 19 | 0.0 | 9.22 | |
8 | Endoribonuclease activity, producing 5'-phosphomonoesters | 19 | 0.0 | 8.07 |
9 | Phosphoprotein phosphatase activity | 22 | 0.0 | 7.2 |
Down-regulated | ||||
1 | Nucleobase, nucleoside, nucleotide kinase activity | 25 | 0.0 | 0.09 |
2 | Telomerase holoenzyme complex | 24 | 0.0 | 0.66 |
3 | Prostaglandin biosynthetic process | 18 | 0.0 | 2.04 |
4 | Prostanoid biosynthetic process | 18 | 0.0 | 1.53 |
5 | Kinase activity | 41 | 0.0 | 1.33 |
6 | Nucleotide kinase activity | 12 | 0.0 | 1.63 |
7 | Kinase regulator activity | 11 | 0.0 | 2.65 |
8 | Pigment granule | 15 | 0.0 | 6.8 |
9 | Melanosome | 15 | 0.0 | 6.04 |
10 | Peptide antigen transport | 10 | 0.0 | 9.18 |